Evaluation of the Efficacy of the Composite WM Formula in Body Weight Change
NCT ID: NCT07097974
Last Updated: 2025-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
40 participants
INTERVENTIONAL
2025-08-31
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Consuming Enzymes and Prebiotics on Body Composition and Blood Biochemical Index
NCT04303481
Efficacy of LN18178 in Improving Muscle Strength, Aerobic Capacity and Body Composition in Healthy Young Males
NCT07092722
Medium Chain Triglycerides (MCT) and Whey Protein Isolate (WPI) for Type 2 Diabetes Patients (Combine)
NCT04905589
Efficacy of Balanced Nutrition Meal Replacement Along With a Caloric Restriction on Body Weight Control
NCT03642925
Breakfast, Exercise and Metabolic Health in Healthy Men
NCT05291065
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will be randomly assigned to one of two groups: one receiving the combined formula WM Formula, and the other receiving a placebo. Each group will take either the WM Formula or placebo, and undergo regular assessments throughout the 4-week study period. Physiological parameters (e.g., height, weight, blood pressure, BMI) and biochemical markers (including liver and kidney function, lipid profile, and blood glucose levels) will be collected at baseline (Week 0), Week 2, and Week 4. In addition, participants will complete appetite assessment questionnaires and other surveys to evaluate changes in appetite and gastrointestinal symptoms.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
WM formula liquid drink
WM formula liquid drink, 50 g/glass jar
WM formula liquid drink
One glass jar (50 g) of the WM formula liquid drink was administered once daily, 1 hour prior to the first meal of the day.
Placebo
The placebo contained the same base ingredients as the WM formula but without the active WM formula component.
Placebo
One glass jar (50 g) of the placebo liquid drink was administered once daily, 1 hour prior to the first meal of the day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
WM formula liquid drink
One glass jar (50 g) of the WM formula liquid drink was administered once daily, 1 hour prior to the first meal of the day.
Placebo
One glass jar (50 g) of the placebo liquid drink was administered once daily, 1 hour prior to the first meal of the day.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body fat percentage: ≥30% for females and ≥25% for males.
* Non-pregnant and non-lactating women who agree to use physical contraceptive methods (e.g., condoms, intrauterine devices) throughout the study period.
Exclusion Criteria
* History of chronic gastrointestinal disorders, seizure disorders or epilepsy, hepatic or renal diseases, malignancies, endocrine disorders, psychiatric illnesses, alcohol or drug abuse, or other major organic diseases based on medical history.
* History of gastrointestinal surgery, organ transplantation, or other major surgeries.
* History of hypoglycemia.
* Known lactose intolerance.
* Chronic diarrhea.
* Acute gastroenteritis within 2 weeks prior to study initiation.
* Known allergy to any ingredient in the investigational product.
* Employees or immediate family members of TCI Co., Ltd.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
TCI Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
TCI Co., Ltd.
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
25-047-A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.